From looking at the program, there were only 2 accepted oral papers for the Cancer of the Pancreas session - the rest are invited or panel discussions.
So,that's excellent.
Also I note a panel discussion on borderline resectable/non-resectable definitions, which would go a long way toward addressing the appropriate patient groups for oncosil treatment in future studies.
Ann: OncoSil PanCO Clinical Trial Presented At ESMO World WCGIC, page-5
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
-0.001(11.1%) |
Mkt cap ! $13.32M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.4¢ | $23.68K | 4.971M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 29 | 23118264 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 5200224 | 7 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| OSL (ASX) Chart |